Based on the original, dualistic hypothesis, generalized anxiety disorder and major depression disorder could be treated by the inhibition of CRF1 with selective antagonists, such as antalarmin, or via the activation of CRF2 with selective agonists, such as Ucn2 or Ucn3 [108,109]. This evidence concerns the gene CRHR2 and generalized anxiety disorder.